|
sTNF/TNFR1 signaling | |
|
sTNF is necessary for the induction of autoimmune diseases [160] | |
Association of TNF and TNFR1 polymorphisms with PD risk [14, 163] | |
Association of TNFR1 polymorphism with MS risk [164] | |
TNFR1 promotes neurodegeneration in retinal ischemia [165] | |
TNFR1 mediates development of pain-induced depressive behavior [166] | |
TNFR1 is essential for the development of MOG35–55 induced EAE [167–169] | |
Inhibition of TNFR1 signaling strongly ameliorates EAE development [169] | |
Blocking of sTNF improves functional outcome in EAE [170, 171] | |
Blocking sTNF attenuates neurodegeneration in AD and PD models [172–174] | |
TNFR1 mediates direct apoptosis of neurons via caspase 8 [175] | |
|
memTNF/TNFR2 signaling | |
|
TNFR2−/− mice show exacerbated neurodegeneration in EAE model [167–169] | |
TNFR2−/− mice show exacerbated neurodegeneration in retinal ischemia [165] | |
TNFR2 promotes OPC proliferation and remyelination [176] | |
TNFR2 protects neurons against glutamate-induced excitotoxicity [142, 143] | |
memTNF dependent activation of NFkB is neuroprotective in EAE [171] | |
TNFR2 rescues neurons from oxidative stress-induced cell death [144] | |
TNFR2 promotes oligodendrocyte maturation [177] | |
TNFR2 promotes oligodendrocyte proliferation and maturation [178] | |
TNFR2 protects OPCs against oxidative stress [179] | |
|